Pietrzak K, Sablińska B, Zieliński J
Department of Gynaecological Oncology, Maria Skłodowska-Curie Memorial Cancer Center and Institute of Oncology Warsaw, Poland.
Eur J Gynaecol Oncol. 1993;14 Suppl:133-9.
The present study was carried out on the material of 486 ovarian cancer patients who received radiotherapy and chemotherapy as adjuvant treatment at the Oncological Gynaecology Clinic at the Maria Skłodowska-Curie Cancer Center-Institute of Oncology in Warsaw in the period 1979-1985, following primary surgery. The clinical stage of disease advancement was determined on the basis of surgery protocols and histological examinations. Radiotherapy was the treatment of choice in patients in stages I and II. Irradiation was applied to the pelvis minor and para aortal nodes (in patients at stage Ia) or to fields covering the entire abdominal cavity (other patients at stage I and II). Chemotherapy was given to stage III and IV patients multi-drug therapy, usually including Cisplatin, Adriamycin, and Cyclophosphamide, or with one drug (monochemotherapy) with the alhylating agents. The largest group of patients under study were women with ovarian cancer in stage I (38.8%), the smallest group consisted of patients in stage IV (8.5%). Patients in stage III represented 37.5% of all the material. Patients aged 50-64 years were most frequently treated (47.3%), the least frequent group were the patients aged over 65 (13.2%). The predominating histological diagnosis was serous cancer type (48.7%), clear-cell cancer was detected least frequently (13.2%). Among all the patients treated 35.4% survived 5 years after treatment, 69% in stage I, 43.8% in stage II, 8.8% in stage III, and 2.5% in stage IV.
本研究以1979年至1985年期间在华沙玛丽亚·斯克洛多夫斯卡-居里癌症中心-肿瘤研究所妇科肿瘤诊所接受放疗和化疗作为辅助治疗的486例卵巢癌患者为研究对象，这些患者均已接受过初次手术。根据手术记录和组织学检查确定疾病进展的临床分期。放疗是I期和II期患者的首选治疗方法。对于Ia期患者，照射范围为盆腔和腹主动脉旁淋巴结；对于其他I期和II期患者，照射范围覆盖整个腹腔。III期和IV期患者采用多药联合化疗，通常包括顺铂、阿霉素和环磷酰胺，或使用一种烷化剂进行单药化疗。研究中最大的患者群体是I期卵巢癌女性（38.8%），最小的群体是IV期患者（8.5%）。III期患者占所有研究对象的37.5%。年龄在50 - 64岁的患者接受治疗的频率最高（47.3%），年龄超过65岁的患者接受治疗的频率最低（13.2%）。主要的组织学诊断是浆液性癌类型（48.7%），透明细胞癌的检出率最低（13.2%）。在所有接受治疗的患者中，35.4%在治疗后存活了5年，I期患者的5年生存率为69%，II期为43.8%，III期为8.8%，IV期为2.5%。
